➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Colorcon
Medtronic
AstraZeneca
McKinsey

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

Patent: 10,092,513

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,092,513
Title:Treatment of diabetes mellitus by long-acting formulations of insulins
Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
Inventor(s): Muhlen-Bartmer; Isabel (Frankfurt am Main, DE), Ziemen; Monika (Frankfurt am Main, DE)
Assignee: SANOFI (Paris, FR)
Application Number:14/781,857
Patent Claims:see list of patent claims

Details for Patent 10,092,513

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Mylan Pharms Inc SEMGLEE insulin glargine INJECTABLE;INJECTION 210605 001 2020-06-11   Get Started for $10 SANOFI (Paris, FR) 2033-04-03 RX search
Eli Lilly And Co BASAGLAR insulin glargine SOLUTION;SUBCUTANEOUS 205692 001 2016-06-17   Get Started for $10 SANOFI (Paris, FR) 2033-04-03 RX search
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started for $10 SANOFI (Paris, FR) 2033-04-03 search
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Get Started for $10 SANOFI (Paris, FR) 2033-04-03 RX search
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started for $10 SANOFI (Paris, FR) 2033-04-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,092,513

Country Patent Number Estimated Expiration
South Africa 201506420   Get Started for $10
World Intellectual Property Organization (WIPO) 2014161837   Get Started for $10
United States of America 2016030339   Get Started for $10
United States of America 2019060233   Get Started for $10
United States of America 2020170945   Get Started for $10
Ukraine 117480   Get Started for $10
Singapore 11201506888V   Get Started for $10
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Baxter
McKinsey
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.